Search Orphan Drug Designations and Approvals
-
| Generic Name: | a lipid nanoparticle encapsulating a messenger RNA for the CRISPR-based gene editor Cas12i2v2.1, and an HAO1- specific guide RNA |
|---|---|
| Date Designated: | 02/02/2025 |
| Orphan Designation: | treatment of primary hyperoxaluria |
| Orphan Designation Status: | Designated |
| FDA Orphan Approval Status: | Not FDA Approved for Orphan Indication |
| Sponsor: |
Arbor Biotechnologies, Inc. 20 Acorn Park Drive, Suite 500 Cambridge, Massachusetts 02140 United States The sponsor address listed is the last reported by the sponsor to OOPD. |
*Data for the Date Designation Withdrawn or Revoked field are shown for designations withdrawn or revoked after 08/12/2013.
-







